Statement of Principles concerning hypopituitarism (Reasonable Hypothesis) (No. 11 of 2019)

The SOP operates through statutory definitions and a list of contributory factors. Key legal concepts are the definition of hypopituitarism (s 7(2)), the notion of a “reasonable hypothesis” (implicit in the SOP’s function under s 196B(2) of the VEA and expressed in the heading), “relevant service” (as defined in the Schedule 1 dictionary), clinical onset and clinical worsening, and the relationship requirement to relevant service (s 10). Each of these shapes evidentiary and legal thresholds that a claimant must meet.

Hypopituitarism for the SOP requires biochemical confirmation of deficient production of one or more pituitary hormones, sufficient to cause clinical signs or to necessitate hormone replacement therapy, and is attributed to loss or damage to pituitary hormone‑secreting cells in the pituitary gland, hypothalamus or pituitary stalk (s 7(2)(a)). The SOP explicitly excludes heritable and congenital forms (s 7(2)(b)). The instrument notes the clinical variability in presentation and lists pituitary hormones for reference in Note 1 to s 7(2). Although the ICD‑10‑AM code E23.0 is noted (s 7(3)), the statutory meaning is the definition in s 7(2).

The factors in s 9 are threshold conditions; the SOP requires that at least one of them must exist before a reasonable hypothesis can be said to be raised connecting hypopituitarism or death from hypopituitarism with service. The factors are expressed as temporally bounded exposures or medical events: for example, infections of the pituitary, hypothalamus, brain or cerebral meninges within five years before clinical onset (s 9(4)); moderate to severe traumatic brain injury within ten years (s 9(6)); concussion within five years (s 9(7)); subarachnoid haemorrhage within ten years (s 9(9)); surgery involving the pituitary or intracranial surgery within ten years (s 9(13)); therapeutic radiation where the pituitary or hypothalamus was in the radiation field (s 9(14)); taking an immune checkpoint inhibitor or interferon within one year (s 9(16)); and high impact contact activity involving blows to the head on at least 50 occasions within a continuous 20 year period with the first occasion at least five years before clinical onset (s 9(8)). Blows to the head and high impact contact activity are defined in the Schedule 1 dictionary, with “blows to the head” given an objective force threshold (equivalent to a forceful punch from a gloved fist) (Schedule 1).

The SOP distinguishes between factors that can cause initial hypopituitarism and those that can materially contribute to or aggravate pre-existing hypopituitarism. Subsections 9(1)-9(18) and 9(19)-9(37) mirror each other as to the kinds of factors, but s 10(2) limits subsections 9(19)-(37) to material contribution to, or aggravation of, hypopituitarism where the condition was suffered or contracted before or during (but did not arise out of) the person’s relevant service. Section 11 requires application of other SOPs where a listed factor refers to an injury or disease already covered by another SOP; those other SOPs’ factors then apply according to their own terms. The Schedule defines a number of technical terms used in the SOP, including immune checkpoint inhibitor, lymphocytic hypophysitis, Hantavirus haemorrhagic fever with renal syndrome, iron overload, and terminal event, among others. Temporal parameters (one year, five years, ten years, 20 years) and frequency thresholds (50 occasions) are central to whether a factor is present.

The SOP’s legal mechanism is therefore a structured, rule‑based gateway: establish a qualifying diagnosis of hypopituitarism under s 7(2); identify a listed factor from s 9 that fits the temporal/frequency definition and relate it to the person’s relevant service under s 10; apply other SOPs where cross‑referenced (s 11). The Repatriation Medical Authority registers its view that there is sound medical‑scientific evidence that such relations can exist (s 8), but the SOP in operation is a statutory test for claims assessment rather than a clinical guideline.

The instrument applies to claimants whose claims fall under section 120A of the VEA or section 338 of the MRCA (s 5). “Relevant service” is defined in the Schedule 1 dictionary to include operational service, peacekeeping service, hazardous service and British nuclear test defence service under the VEA, and warlike and non‑warlike service under the MRCA. Therefore, persons who rendered any of those classes of service and who lodge claims that invoke the VEA or MRCA causal connection tests are the primary cohort affected by the SOP.

Directly affected claimants include veterans, members of peacekeeping forces, and members of the Forces covered by the MRCA categories, where those persons assert that hypopituitarism or death from hypopituitarism is connected to their service (s 8; Schedule definition of relevant service). The instrument also affects families and estates where death from hypopituitarism is claimed, since s 7(5) explicitly includes death from a terminal event or condition that was contributed to by the person’s hypopituitarism. Medical practitioners, forensic clinicians and other experts who provide evidence for claims are affected because the SOP sets the statutory criteria and temporal windows that evidence must address (for example biochemical documentation, timing of onset, and documentation of factors such as surgery, infection, TBI, radiation, or drug treatment). Administrators and decision makers assessing claims must apply the SOP’s thresholds (s 9) and relation test (s 10).

Certain groups outside of conventional service personnel are indirectly affected where their medical or exposure histories intersect with the SOP’s factors. For example, those who participated in sustained high impact contact activities (as defined) and who later develop hypopituitarism will be affected by the SOP’s threshold for blows to the head and the explicit frequency/time conditions (s 9(8) and Schedule 1). Women who experienced severe peripartum or postpartum haemorrhage or lymphocytic hypophysitis related to pregnancy are identified in the factors (s 9(11) and s 9(18)), so service personnel with such obstetric histories are implicated. Persons who underwent therapeutic cranial radiation where the pituitary/hypothalamus was irradiated (s 9(14)) or who received immune checkpoint inhibitors or interferon therapy within the relevant one year window (s 9(16) and s 9(34) for worsening) are also within the instrument’s scope.

The instrument also affects the bodies that maintain related SOPs. Section 11 provides that where a listed factor refers to an injury or disease already covered by another SOP made under subsection 196B(2) of the VEA, the factors in that other SOP apply in accordance with its terms. This creates a network effect between SOPs and channels some evidentiary questions to the SOP that the Repatriation Medical Authority has already determined for other conditions.

Lastly, the SOP affects decisionmakers’ and claimants’ evidentiary strategies and resource allocation. Because the SOP imposes precise temporal windows and definitional thresholds (for example biochemical documentation, specific time windows, frequency of exposures), claimants will need to marshal medical records and service records aligned to those statutory specifications. The onus is on establishing that a listed factor existed and that it is related to relevant service (s 9; s 10(1)); the instrument therefore shapes who bears the burden of compiling particular kinds of evidence.

The SOP creates statutory tests and associated procedural effects rather than direct duties or civil penalties. The Repatriation Medical Authority’s role is to determine and publish the Statement of Principles under subsection 196B(2) of the VEA, which it has done by setting the definition and factors (s 3; s 8). Decision‑makers who assess claims under the VEA or MRCA must apply the SOP where those claims fall within s 120A of the VEA or s 338 of the MRCA (s 5). The operational duty for claimants is to establish facts that satisfy the statutory tests set out in the SOP so that a reasonable hypothesis of connection between hypopituitarism (or death from it) and relevant service is raised.

Specific claimant requirements arising from the SOP include demonstrating a diagnosis of hypopituitarism that meets the statutory meaning (biochemical evidence and/or pituitary hormone replacement therapy, and attribution to loss or damage to hormone-secreting cells in the pituitary/hypothalamic region) and ensuring that congenital or heritable forms are not being asserted (s 7(2)). Claimants must show at least one of the factors in s 9 existed; each factor has temporal or frequency limits which must be matched to the clinical onset or clinical worsening dates. The SOP also differentiates between initial causation and aggravation or material contribution: subsections 9(19)-(37) apply only to material contribution to or aggravation of hypopituitarism where the person’s hypopituitarism was suffered or contracted before or during (but did not arise out of) their relevant service (s 10(2)). Thus when a claimant relies on those latter factors, the legal framing must be that of aggravation or material contribution rather than primary causation.

There is a right implicit in the instrument for a claimant to have a “reasonable hypothesis” considered where the statutorily listed facts exist. This is the legal effect of setting the SOP under the VEA process: if the SOP’s factors are met and related to relevant service, the claim‑assessment process recognises that a reasonable hypothesis has been raised. Section 11 gives claimants a right to the application of other SOPs where a factor in this SOP refers to an injury or disease already covered by another Statement , the other SOP’s factors then apply according to that Statement. For death claims, the SOP clarifies that death from hypopituitarism is included if the terminal event or condition was contributed to by the hypopituitarism (s 7(5)), and the Schedule defines “terminal event” with a non‑exhaustive list of proximate causes.

Decision‑makers must, accordingly, treat the statutory definition in s 7(2) as controlling even if an ICD‑10‑AM code exists (s 7(3)-(4)). The SOP requires that the existence of a factor be related to the relevant service rendered by the person (s 10(1)). In practice, these operate as duties on administrative decision‑makers to assess whether the claimant has produced sufficient evidence of the factor and its linkage to service. The SOP does not itself prescribe procedural steps for decision‑makers beyond the thresholds; it operates as the medical/legal standard embedded in the statutory claims process.

The Schedule supplies more granular definitions that impose evidentiary particularity. For instance, “blows to the head” is defined by an equivalence to a forceful punch from a gloved fist, which translates into a concrete standard for expert evidence (Schedule 1). The immune checkpoint inhibitor definition in the Schedule links specific drug classes to the factor in s 9(16) and the amendment history shows that the definition has been updated, so parties have a right to rely on the current compilation and must check for amendments (Schedule 1; Endnote 3 and 4).

The Statement of Principles itself contains no criminal provisions, monetary fines or direct civil penalties. It is an instrument that functions as a statutory evidentiary and causal framework used in assessment of entitlements under the VEA and MRCA. The SOP therefore enforces its standards through administrative decision‑making: whether a claimant has raised a reasonable hypothesis connecting hypopituitarism, or death from it, with relevant service will affect entitlement determinations under s 120A of the VEA and s 338 of the MRCA by the relevant decision‑making body responsible for applying those Acts (s 5).

The Repatriation Medical Authority expresses a view that there is sound medical‑scientific evidence that hypopituitarism and death from it can be related to relevant service (s 8). That expression is not an enforcement action but the basis upon which the SOP operates in claims processes. Enforcement in the sense of administrative consequence arises when a decision makes use of the SOP to accept or reject a claim; adverse determinations will then be subject to the review and appeal processes established under the VEA or MRCA frameworks, not set out in this SOP.

There are no penal sanctions in the SOP text for misstatements, fraudulent claims, false evidence, or non‑compliance. Any penalty regime relevant to such conduct would be contained in the VEA, MRCA or other statutes, not in this SOP. The SOP’s effect, therefore, is to shape entitlement outcomes through its definitional and factor tests and to direct fact‑finding rather than to create enforceable offences.

Administrative enforcement risk arises in practice in several forms. If a claimant cannot establish a listed factor under the defined temporal windows and thresholds (s 9), or if they cannot show that the factor is related to relevant service (s 10(1)), a decision‑maker will have grounds to find no reasonable hypothesis is raised and decline service‑connected entitlement. Cross‑reference to other SOPs (s 11) can either expand or narrow evidentiary expectations depending on the other SOP’s terms, so claimants and advisers must monitor which SOP applies to any referred injury or disease. The instrument’s amendments (Endnotes 3 and 4) mean that claimants and decision‑makers must ensure they apply the version current at the time of decision; failure to do so may affect administrative outcomes and potential review avenues.

In short, the SOP exerts enforcement impact indirectly by setting the statutory gates used by administrators to determine entitlements under the VEA and MRCA. It does not itself create penalties, but non‑satisfaction of its tests will have material administrative consequences for claimants seeking service connection for hypopituitarism or death from it.

The SOP is explicitly made under subsection 196B(2) of the VEA (s 3), and it applies to claims to which section 120A of the VEA or section 338 of the MRCA apply (s 5), thereby situating it within the statutory claims and entitlements regimes of the VEA and MRCA. The SOP’s role is to provide the Repatriation Medical Authority’s determination of medical‑scientific factors that can establish a reasonable hypothesis of connection between an injury/disease and relevant service; this is a statutory mechanism set in the VEA framework and used by decision‑makers under the VEA and MRCA.

Section 11 creates an express interaction mechanism between this SOP and other SOPs made under subsection 196B(2): where a factor in s 9 of this SOP refers to an injury or disease that is the subject of another SOP, the factors in that other SOP apply according to its terms. That means the legal analysis for a claimant can involve multiple SOPs. For example, if a factor refers to traumatic brain injury and there is a separate SOP dealing with TBI, the TBI SOP’s factors will govern how that factor is treated. This cross‑reference can result in layered application: this SOP identifies the relevance of a named injury or disease, while the referenced SOP supplies the detailed factors that must be present for that injury/disease to be accepted as a link.

The SOP refers to the ICD‑10‑AM code E23.0 but makes clear that for the purposes of the SOP the statutory definition in s 7(2) controls (s 7(3) and s 7(4)). The reference to ICD‑10‑AM is therefore classificatory and external; decision‑makers should not substitute a mere code for the statutory definitional requirements set out in s 7(2), which require biochemical confirmation or therapy and exclude congenital/heritable forms.

The Schedule defines “relevant service” (including operational, peacekeeping, hazardous, British nuclear test defence service, warlike/non‑warlike service) and therefore interacts with the VEA and MRCA definitions and eligibility rules. Section 10 requires that the existence of any factor in s 9 must be related to the person’s relevant service, introducing a causal nexus that must be proven within the VEA/MRCA statutory framework. Section 10(2) provides a specific interactional rule for subsections 9(19)-(37), limiting those factors to material contribution or aggravation where the hypopituitarism pre‑existed service or was suffered during service but did not arise out of it; this is an apportionment‑type rule that affects how pre‑existing conditions are handled under the Acts.

Amendment history and the compilation notes (Endnotes 3 and 4) show interaction with the Legislative Instruments Act 2003 and the Legislation Act 2003 (referenced in the endnotes abbreviation keys). Amendments that alter definitions or the time windows for factors will change how the SOP interacts with claim assessments and potentially with other SOPs that cross‑refer to this instrument.

Finally, because the SOP is part of a family of SOPs used across VEA and MRCA assessments, it interacts operationally with administrative review and appeal mechanisms under those Acts. The SOP sets the medical/legal standard; disputes over its application will be processed under the decision review or merits review routes available under the VEA/MRCA and other review jurisdictions, although those processes and remedies are not detailed in this instrument.

The compilation and endnotes record the instrument’s origins and subsequent amendments. The Statement of Principles concerning hypopituitarism (Reasonable Hypothesis) (No. 11 of 2019) was registered on 3 January 2019 and commenced on 28 January 2019 (Endnote 3). Subsequent amendments recorded in the legislation history are Amendment No. 81 of 2021, registered 29 June 2021 and commencing 26 July 2021, and Amendment No. 53 of 2022, registered 2 May 2022 and commencing 30 May 2022 (Endnote 3). The compilation date shown in the instrument is 30 May 2022 and the compilation includes amendments up to Amendment No. 53 of 2022.

The amendment history table in Endnote 4 sets out changes at the provision level. It records that:

• Section 2 was repealed by the Legislation Act 2003, s 48D (rep LA s 48D);
• Section 4 was repealed by the Legislation Act 2003, s 48C (rep LA s 48C);
• Subsection 7(2)(a) was amended by No. 81 of 2021 (am No. 81 of 2021);
• Subsections 9(16) and 9(34) were revised by No. 53 of 2022 (rs No. 53 of 2022); and
• The Schedule 1 dictionary entry for “immune checkpoint inhibitor” was revised by No. 53 of 2022 (rs No. 53 of 2022).

Those line items indicate the specific areas of the SOP that were updated. The amendment to subsection 7(2)(a) in 2021 suggests the statutory definition of hypopituitarism was refined or clarified at that time, while the 2022 revisions adjusted the drug‑related factors (9(16) and 9(34)) and the Schedule definition for immune checkpoint inhibitors, reflecting evolving medical treatment relevance. The compilation notes indicate that any amendments not yet commenced as at the compilation date are not shown in the text; uncommenced amendments would be underlined in the endnotes per the compilation conventions, although the present compilation includes amendments up to No. 53 of 2022 that had commenced on 30 May 2022 (Compilation notes).

Users of the SOP must be alert to the fact that the text of the compiled law shows amendments that are in force at the compilation date and that uncommenced amendments are identified in the endnotes. The endnotes also explain treatment of misdescribed amendments and provide an abbreviation key to interpret the amendment history entries (Endnotes 1 and 2). For legal practice, this means confirming which version of the SOP is current at the time a claim is made or decided, and checking the amendment history for any changes to definitions or factor timeframes (Endnote 4 entries identifying specific provision amendments).

The text of this Statement of Principles and its endnotes do not record any judicial decisions or litigation arising from the SOP itself. The instrument is an administrative medical‑scientific determination under subsection 196B(2) of the VEA and the compilation’s endnotes are limited to legislative history and amendment history; they do not include court or tribunal decisions. The Schedule and the body of the SOP do not quote or cite any cases, nor do the endnotes include references to litigation.

Because the SOP cross‑refers to other SOPs under subsection 196B(2) (s 11), disputes over causation that involve this SOP may intersect with litigation or review concerning other SOPs, but any such litigation is not summarised in this instrument. The absence of litigation history in the compilation means that users must turn to external legal databases, tribunal decisions, or administrative law reports to discover any cases that might interpret or test the application of this SOP in particular fact scenarios.

Practitioners should be aware that administrative decisions applying SOPs are typically subject to merits review and judicial review processes under the relevant statutory frameworks (VEA/MRCA and administrative law), and that interpretation of the SOP’s temporal windows, definitions, and causation thresholds may be contested in those forums. The SOP itself, however, contains no catalogue of such disputes or outcomes; the compilation is silent on precedent and provides no litigation analysis. Consequently, where precedent or adjudicative guidance is important, advisers will need to supplement this instrument with targeted searches of tribunal and court decisions applying or construing this or cross‑referenced SOPs.

The SOP contains several technical particularities and drafting choices that create potential pitfalls for claimants, advisers and decision‑makers. These are concrete issues that frequently arise in practice when statutes use time‑bounded, definition‑rich lists of factors.

1. Definition controls over ICD code: Although the SOP notes that hypopituitarism attracts ICD‑10‑AM code E23.0, it expressly states that for SOP purposes the meaning of hypopituitarism is the statutory definition in s 7(2). Practitioners must not rely on an ICD code alone; the claimant must meet the biochemical/therapy criteria in s 7(2)(a) and exclude congenital or heritable forms under s 7(2)(b). Relying on diagnosis codes without showing biochemical documentation or replacement therapy risks rejection.

2. Temporal and frequency thresholds are strict: Many factors in s 9 include precise time windows (one year, five years, ten years) or frequency thresholds (for high impact contact activity, at least 50 occasions within a continuous 20 year period, with the first occasion at least five years before onset, s 9(8)). Failure to map clinical onset or worsening dates correctly against these limits can lead to unsuccessful claims. For example, concussion within five years is a different threshold to moderate to severe TBI within ten years (s 9(6)-(7)), which matters for evidence gathering.

3. Distinction between initial causation and aggravation: Subsections 9(19)-(37) mirror earlier factors but s 10(2) limits them to material contribution to or aggravation of hypopituitarism where the hypopituitarism was suffered or contracted before or during (but did not arise out of) relevant service. This is a functional apportionment rule: the later factors cannot be used to establish initial causation if the hypopituitarism arose after service. Lawyers must be careful in pleading whether a factor is relied upon as a cause or as an aggravating influence and must produce evidence fitting the “material contribution/aggravation” framing.

4. “Inability to obtain appropriate clinical management” is broad but must be related to service: Subsection 9(37) is potentially wide and may be attractive for claimants who experienced service‑connected access issues. However s 10(1) requires the existence of any factor to be related to the relevant service, so link evidence is required. The SOP does not define “appropriate clinical management” in the Schedule, so proof may hinge on contextual medical evidence and documentation of access attempts.

5. Objective definitions: Schedule definitions provide concrete evidentiary standards. “Blows to the head” is defined by an objective force equivalence (forceful punch from a gloved fist), which sets a higher threshold than subjective descriptions of blows (Schedule 1). High impact contact activity uses that concept and adds a quantitative frequency test (s 9(8)). Where a claimant asserts sports‑related exposure, both the subjective history and corroborative evidence (team records, contemporaneous medical notes, imaging showing brain injury sequelae) should be marshalled to meet the statutory standard.

6. Interacting SOPs: Section 11 requires application of other SOPs where a factor refers to an injury or disease covered elsewhere. That can introduce complexity and the risk of circularity if practitioners do not identify the correct cross‑referenced SOP. Failure to apply the other SOP’s factors correctly can misstate the legal test.

7. Recent amendments may change factor scope: The amendment history records changes to subsection 7(2)(a) in 2021 and to the immune checkpoint inhibitor entries in 2022 (Endnote 4). Practitioners must check the operative version for a given claim date. Using an outdated compilation could lead to misapplication of the factor for immune checkpoint inhibitor exposure or to reliance on an earlier definition of hypopituitarism.

8. Death claims require proving contribution to terminal event: Section 7(5) includes death from hypopituitarism where the terminal event or condition was contributed to by hypopituitarism, and the Schedule lists examples of terminal events. Practitioners should note that the link is to the terminal event’s contribution by hypopituitarism, not automatic inclusion of any death where hypopituitarism is present. Medical causation evidence will need to address proximate cause and contribution to the terminal event.

9. Exclusions for congenital/heritable forms: The statutory exclusion in s 7(2)(b) removes congenital and heritable hypopituitarism from the SOP’s scope. Claimants whose hypopituitarism is congenital will not benefit from this SOP, and advisers should seek early evidence (genetic, perinatal records) to demonstrate whether exclusion applies.

10. Burden of proof and relation to service: The SOP sets the factors that raise a reasonable hypothesis; it does not remove the need to link the factor to relevant service under s 10(1). The existence of a factor must be related to relevant service, so contemporaneous service records, exposure logs, medical notes during or after service, and service incident reports may be necessary. The SOP provides thresholds but does not alter the basic requirement of a connection to service.

These “gotchas” are concrete operational points where failing to align medical evidence, service records and legal framing with the SOP’s specific language will materially affect claim outcomes.

Follow a structured, section‑by‑section evidence plan tied to the SOP’s statutory language.

1. Confirm applicability (s 5): First ensure the claim is one to which section 120A of the VEA or section 338 of the MRCA applies. Confirm the claimant’s service meets the Schedule’s definition of “relevant service” (operational, peacekeeping, hazardous, British nuclear test defence service, warlike or non‑warlike service). If the claim does not fall under those statutory provisions, this SOP will not apply.

2. Establish the diagnosis under s 7(2): Obtain contemporaneous and historical medical records showing biochemical documentation of deficient production of one or more pituitary hormones. Evidence can include hormone assay results, dynamic endocrine testing, documented clinical signs attributable to hormone deficiency, and records indicating ongoing or required pituitary hormone replacement therapy. Ensure the records address whether the hypopituitarism is heritable or congenital; if so, the SOP excludes those forms (s 7(2)(b)).

3. Determine clinical onset and/or worsening dates: Identify the dates of clinical onset and any clinical worsening. Many factors in s 9 are tied to the timing of onset or worsening (for example within five or ten years). Accurate dating will determine which factors may be in play.

4. Map factors to s 9 precisely: Review s 9 and the Schedule dictionary to select at least one qualifying factor. For each factor relied upon, compile evidence tailored to that factor:

   • Autoimmune pituitary disorder: endocrinology notes, autoantibody tests, imaging, histology if available (s 9(1) and s 9(19)).
   • Infections (viral, bacterial, fungal, protozoal) of pituitary/hypothalamus/brain/meninges within five years: infectious disease diagnoses, microbiology, imaging and surgical pathology (s 9(4) and s 9(22)).
   • HIV prior to onset (s 9(3) and s 9(21)): HIV diagnosis dates and treatment history.
   • Moderate to severe TBI or concussion: acute hospital records, imaging (CT/MRI), specialist reports, and objective severity markers corresponding to ten/v five year windows (s 9(6)-(7)).
   • High impact contact activity: documentary support of participation, frequency records, team or club logs, medical notes documenting head impacts and the history showing at least 50 occasions in a continuous 20 year period with first occasion at least five years before onset (s 9(8); Schedule 1).
   • Surgery/radiation: operative reports, radiation therapy treatment fields and dosimetry specifying pituitary/hypothalamus inclusion, and dates (s 9(13)-(14)).
   • Drug exposures: immune checkpoint inhibitors or interferons within one year before onset/worsening,provide oncology treatment records, drug administration dates, and relevant pharmacology notes (s 9(16); Schedule).
   • Intranasal cocaine use causing septal/palatal/paranasal sinus destruction: ENT notes, imaging, surgical records (s 9(17)/(35)).
   • Pregnancy‑related lymphocytic hypophysitis: obstetric records proving pregnancy within six months before onset/worsening and endocrinology corroboration (s 9(18)/(36)).

5. Establish relation to relevant service (s 10(1)): Provide evidence linking the factor to the person’s service. This may include deployment records, exposure reports, incident reports, medical encounters during service, or contemporaneous reporting of injuries or infections. For aggravation factors in subsections 9(19)-(37), show that hypopituitarism pre‑existed before service or was suffered during service but did not arise out of service, then demonstrate material contribution or aggravation by the relevant factor (s 10(2)).

6. Cross‑reference other SOPs where applicable (s 11): If a chosen factor refers to an injury or disease covered by another SOP, obtain and comply with that SOP’s factors and terms. For example, if relying on traumatic brain injury as the connecting factor, determine if a TBI SOP exists and gather the specific evidence that the TBI SOP requires.

7. Death claims (s 7(5) and Schedule): For death from hypopituitarism, produce medical evidence linking hypopituitarism to the terminal event(s). Use clinical opinions that address contribution to proximate cause and align with the Schedule’s examples of terminal events (pneumonia, respiratory or circulatory failure, cardiac arrest, cessation of brain function).

8. Address “inability to obtain appropriate clinical management” (s 9(37)): Document attempts to obtain care (referrals, appointments, refusals, service health system constraints), contemporaneous communications, and clinical consequences of lack of management. Tie lack of access to service where necessary per s 10(1).

9. Ensure contemporaneous medical/administrative corroboration: The SOP’s concrete thresholds favour contemporaneous documentation. Where possible, secure medical imaging reports, operative notes, treatment summaries, laboratory results, service records and any corroborating third‑party records.

10. Verify version and amendments: Confirm you are applying the operative version of the SOP for the claim date. Endnotes show amendments to s 7(2)(a) (No. 81 of 2021) and changes to factors concerning immune checkpoint inhibitors (No. 53 of 2022) , check the compilation current at decision time (Endnotes 3 and 4).

11. Expert opinions: Use clinical experts to link the documented factor to hypopituitarism and to explain timelines in terms of the SOP’s windows. Experts should address biochemical criteria, causation or contribution to terminal events for death claims, and the relationship to service.

12. Prepare legal framing: When lodging the claim, frame the factual case to match statutory categories: (a) diagnosis satisfying s 7(2); (b) existence of a listed factor in s 9 under the precise timeframe/frequency; (c) relation to relevant service under s 10; and where applicable (d) reliance on other SOPs under s 11.

Following this checklist will align evidence with the statutory structure of the SOP and reduce risks arising from misapplied definitions, incorrect temporal mapping, or failure to demonstrate relation to relevant service.